Fennec Pharmaceuticals Inc. Common Stock (FENC)
Fennec Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare and life-threatening pediatric diseases. The company's lead candidate, seek to address unmet medical needs by advancing therapies that improve patient outcomes in areas such as oncology and pain management.
Company News
Fennec Pharmaceuticals reported strong Q2 2025 earnings with $9.7 million in net product sales, representing 33% year-over-year growth. The company is expanding internationally through partnerships, securing formulary wins, and preparing for potential milestone events in Europe and Japan.
Fennec Pharmaceuticals reported strong first-quarter 2025 financial results, with total net revenues up 18% year-over-year. The company attributed the positive momentum to its refined sales strategy and enhanced patient support services.
Adherex Technologies (FENC) delivered earnings and revenue surprises of -16.33% and 142.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts have provided the following ratings for Fennec Pharmaceuticals (NASDAQ:FENC) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 1 0 0 0 According to 4 analyst offering 12-month price targets in the...